ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1577139
Real-world experience and prognostic factors in ovarian carcinosarcoma: A single-center retrospective study from China
Provisionally accepted
- Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Ovarian carcinosarcomas (OCS) is a rare type of ovarian cancer. Due to its low incidence, studies are limited to several case reports/case series and small-scale retrospective study. We carried out this study to explore prognostic factors and treatment strategies for OCS. Methods: Patients diagnosed with OCS between March 2012 and October 2023 at Jiangsu Cancer Center were enrolled in this study. Baseline Characteristics, treatment strategies and survival of all enrolled patients were recorded.Kaplan-Meier analysis with a log-rank Mantel-Cox test was used to compare progression-free survival (PFS) between different groups. Results: Twenty-six patients met inclusion criteria. The median PFS of all enrolled patients was 17.53 months. We firstly demonstrated that patients with ascites ≥500 ml (27.83 months vs. 13.7 months, p=0.12, HR 0.72), age ≥58 years (22.93 months vs. 13.53 months, p=0.354, HR 0.62), diameter of tumor＜10cm (27.83 months vs. 12.80 months, p=0.095, HR 0.36), p=0.093, HR 0.39) had a trend of better prognosis. Five patients underwent genetic testing, 4 of whom were homologous recombination deficiency (HRD)-positive and treated with PARP inhibitor (PARPi). The median PFS of the 4 patients was 22.68 months. Conclusions: Our study demonstrated that age at diagnosis, diameter of tumor, Ki-67 index, and volume of ascites may be prognostic factors of OCS. Patients with HRD positive/ BReast CAncer gene (BRCA) mutation may benefit from PARPi.
Keywords: Ovarian carcinosarcomas, prognostic factors, PARP inhibitors, Homologous recombination deficiency, Breast cancer gene
Received: 15 Feb 2025; Accepted: 22 May 2025.
Copyright: © 2025 Ji, Zhuo and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xianzhong Cheng, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.